An interventional study of Low-Calorie Diet Rich in Medium-Chain Triglycerides (MCTs) Based on Traditional Minangkabau Foods in Metabolically Unhealty Obese, Dyslipidemia and Diabetes (DM), sponsored by Andalas University. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Andalas University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to investigate the effect of a low-calorie diet rich in medium-chain triglycerides (MCTs) based on traditional Minangkabau foods on metabolic biomarkers in individuals with obesity. The traditional Minangkabau foods used in this study consist primarily of coconut milk-based dishes, which contain coconut oil as a natural source of MCTs. The metabolic biomarkers assessed include body mass index (BMI), waist circumference, systolic and diastolic blood pressure, body fat percentage, fasting blood glucose levels, lipid profile, leptin concentrations, and DNA methylation of the leptin gene promoter. Based on these metabolic biomarker measurements, participants will be classified into metabolic obesity phenotypes, namely metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO). The researchers hypothesize that the provision of a low-calorie, MCT-rich diet based on traditional Minangkabau foods will have a significant effect on metabolic biomarkers and metabolic status in individuals with obesity.
This study was conducted within the Faculty of Medicine and the Faculty of Public Health at Andalas University, Padang, and received ethical approval from the Research Ethics Committee of the Faculty of Medicine, Andalas University. The study population consisted of educational staff with a body mass index (BMI) greater than 25 kg/m². Study participants were educational staff who agreed to participate and provided written informed consent. A total of 40 participants were included in the study, comprising 20 participants in the intervention group and 20 participants in the control group.
The study was conducted over a period of 12 weeks (90 days). One week prior to the intervention, dietary intake was assessed using the 24-hour food recall method. Anthropometric measurements were performed using calibrated instruments by trained personnel.
Participants in both the intervention and control groups underwent a one-week pre-intervention period (baseline period, from day -6 to day 0), during which they were instructed not to consume any supplements. Anthropometric measurements, blood pressure, body fat percentage, fasting blood glucose levels, lipid profile, leptin concentrations, and DNA methylation of the leptin gene promoter were assessed on day 0 and day 90.
Dietary intake data obtained from the 24-hour food recall interviews were analyzed using the NutriSurvey 2005 software. The dietary intervention was designed to provide an energy deficit of 500-600 kcal compared with participants' habitual daily intake. The diet was based on traditional Minangkabau foods.
Participants in the intervention group were provided with daily menu plans for breakfast, lunch, and dinner. The dietary intervention was prepared independently by participants in accordance with the dietary guidelines and menus provided. In contrast, the control group followed a standard nutritionally balanced diet according to individual requirements. Participants were instructed to record their daily food intake in a food diary, which was collected and evaluated twice weekly (on weekdays and weekends). In addition, the research team monitored and motivated all participants through WhatsApp groups. Data analysis was performed using SPSS software.
1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
This study's planned enrollment of 40 is below the median of 100 across 988 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Andalas University is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low-Calorie Diet Rich in Medium-Chain Triglycerides (MCTs) Based on Traditional Minangkabau Foods Participants in the intervention group received a nutritionally balanced low-calorie diet rich in medium-chain triglycerides (MCTs) derived from traditional Minangkabau foods. The dietary intervention was designed to provide an energy deficit of 500-600 kcal compared with participants' habitual daily intake. Assessments were conducted before and after the intervention period.
Other: Low-Calorie Diet Rich in Medium-Chain Triglycerides (MCTs) Based on Traditional Minangkabau Foods
Standard Nutritionally Balanced Diet Participants in the control group received a standard nutritionally balanced diet without specific emphasis on MCT content. This diet was not designed to induce an energy deficit and was instead tailored to participants' usual daily dietary habits and energy requirements. Assessments were conducted before and after the study period.
Participants in the intervention group received a nutritionally balanced low-calorie diet rich in medium-chain triglycerides (MCTs) derived from traditional Minangkabau foods. The dietary intervention was designed to provide an energy deficit of 500-600 kcal compared with participants' habitual daily intake. Assessments were conducted before and after the intervention period.
Change from baseline in body mass index (BMI).
BMI is calculated as body weight in kilograms divided by the square of height in meters (kg/m²).
Time frame: After 12 weeks
Change from baseline in waist circumference.
Waist circumference is measured around the abdomen at the level of the umbilicus.
Time frame: After 12 weeks
Change from baseline in body fat percentage
Body fat percentage is assessed using bioelectrical impedance analysis (BIA).
Time frame: After 12 weeks
Change from baseline in systolic and diastolic blood pressure
Blood pressure is measured using a digital tensimeter.
Time frame: After 12 weeks
Change from baseline in fasting blood glucose levels.
Fasting blood glucose levels are measured using a clinical chemistry analyzer.
Time frame: After 12 weeks
Change from baseline in lipid profile.
The lipid profile includes total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol. Measurements are performed using a clinical chemistry analyzer (photometer).
Time frame: After 12 weeks
Change from baseline in serum leptin.
Serum leptin concentrations are measured using appropriate laboratory methods (ELISA).
Time frame: After 12 weeks
Change from baseline in DNA methylation of the leptin gene promoter.
DNA methylation status of the leptin gene promoter is assessed using MSP (Methylation-Specific PCR).
Time frame: After 12 weeks
Change in metabolic status.
Metabolic status is classified into Metabolically Healthy Obesity (MHO) and Metabolically Unhealthy Obesity (MUHO) based on the number of metabolic abnormalities present. * MHO is defined as the presence of 0-1 metabolic abnormality. * MUHO is defined as the presence of ≥2 metabolic abnormalities. These metabolic abnormalities included elevated fasting blood glucose levels, increased blood pressure, enlarged waist circumference, elevated triglyceride levels, and reduced high-density lipoprotein (HDL) cholesterol levels.
Time frame: After 12 weeks
Plan to share: No
Start is estimated for Apr 2026; primary completion for May 2026, 1 month later.
Of 194 non-industry interventional studies with no phase under Dyslipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 1 month is below that.
Counting every sponsor, half of 205 studies reached it within 16 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Andalas University